Molecular Biology of Cell Signaling and Immunology Targets in Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 320
Special Issue Editor
Interests: immune response; inflammation; macrophages; dendritic cells; stem cells; signaling; calcium; tumor microenvironment; hematopoiesis; radiation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
More than 150 years ago, based on the observation of rare cases of spontaneous cancer regression after bacterial infection, Wilhelm Busch, a German surgeon, intentionally infected a patient with Streptococci to induce erysipelas, trigger a vigorous acute inflammatory reaction, and ultimately a skin cancer regression. This approach was probably one of the first attempts to leverage the immune response against cancer cells. More recently, the seminal studies of the Nobel Laureate James Allison, led to the identification of the first immune checkpoint inhibitor (ICI), paving the way for cancer immunotherapy. Large molecules (e.g., Immune checkpoints inhibitors-ICI, Bi-specific antibodies-BiTE) alongside the adoptive transfer of engineered autologous lymphocytes (e.g., CAR-T) are the pillars of the current cancer immunotherapy. However, a better understanding of the cellular and molecular components of the mechanisms regulating the anti-tumor immune response locally and systemically is driving the identification of an increasing number of novel potential druggable targets to stimulate the anti-tumor immune response. Consequently, small molecules are emerging as a promising class of immunoregulatory drugs to shape the tumor microenvironment and overcome the limitations of ICI, BiTE, and CAR-T therapies. This special issue will collect studies focusing on the cellular and molecular mechanisms regulating the anti-tumor immune response, which led to the characterization of signal pathways, druggable targets, and small molecules to stimulate the anti-cancer immune response.
Dr. Luigi Racioppi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- signaling in tumor associated immune cells
- tumor-associated immune cells metabolism
- toll-like receptor (TLR) agonists
- (NOD)-like receptor (NLR) agonists
- STING-signaling agonists
- kinase inhibitors
- protein degraders
- small interfering RNA (siRNA)
- tumor microenvironment
- aptamers
